AXSOME THERAPEUTICS, INC.

Drug pipeline (3)

Asset	Stage	Revenue	Trials	Status
AUVELITY	approved	$180.3MQ2 2026	1	approved
SUNOSI	approved	$35.8MQ2 2026	0	—
SYMBRAVO	approved	$2.3MQ2 2026	14	approved

Revenue is the latest quarter the company reported for that product, from SEC filings; a fourth quarter is the year less nine months when no filing states one. Trial counts are of the product's ingredients, deduplicated by trial, so products sharing an ingredient share trials.

Clinical trials (36)

NCT ID	Phase	Status	Start	Completion	Sponsor name	Title
NCT02746068	phase3	unknown	2016-03-01	2020-12-01	Axsome Therapeutics, Inc.	A Study to Assess the Efficacy and Safety of AXS-02 in Subjects With Knee OA Associated With Bone Marrow Lesions
NCT05557409	phase3	completed	2022-09-06	2024-11-21	Axsome Therapeutics, Inc.	A Study to Assess the Efficacy and Safety of AXS-05 in Subjects With Alzheimer's Disease Agitation
NCT02741791	phase3	completed	2016-03-01	2020-03-20	Axsome Therapeutics, Inc.	A Study to Assess the Efficacy and Safety of AXS-05 in Subjects With Treatment Resistant Major Depressive Disorder
NCT05059223	phase3	completed	2021-09-15	2024-03-15	Axsome Therapeutics, Inc.	A Study to Assess the Efficacy and Safety of AXS-12 (Reboxetine) in Patients With Narcolepsy
NCT07717892	phase3	recruiting	2026-06-25	2028-06-30	Axsome Therapeutics, Inc.	A Study to Assess the Efficacy and Safety of Solriamfetol in Adolescents With ADHD

FDA applications (3)

Application

Approved

Type

Applicant

Products

NDA 215431

2025-01-30

NDA

AXSOME THERAPEUTICS INC

NDA 215430

2022-08-18

NDA

AXSOME THERAPEUTICS INC

NDA 211230

2019-06-17

NDA

AXSOME MALTA LTD